BioCentury
DATA GRAPHICS | Data Byte

The TREM1 pipeline gets one more therapy

Celsius throws its hat in the ring for a first-in-class IBD treatment

March 25, 2022 12:22 AM UTC

With its disclosure of TREM1 as the target of its lead program, Celsius could have a first-in-class therapy for inflammatory bowel disease, although at least two other biotechs have developed molecules addressing TREM1 for other indications.

Celsius Therapeutics Inc. said Thursday its anti-TREM1 antibody, CEL383, could reach the clinic as soon as early 2023. The biotech discovered the molecule using its Single Cell Observations for Precision Effect (SCOPE) platform, identifying TREM1 as an amplifier of inflammation that modulates the behavior of cell subsets that drive resistance to anti-TNF therapies...